Background: Glomerular capillary injuries result in proteinuria, previously reported to be a risk factor for renal allograft dysfunction. According to the Banff 97 Working Classification of Renal Allograft Pathology, ‘double contours’ in glomerular capillary loops (GC-DC) were suggested to be most specific for chronic transplant glomerulopathy. Tenascin-C (TN), a component of extracellular matrix, is known to be overexpressed in various conditions. Methods: TN immunostaining was performed by the labeled streptavidin biotin method. The correlations between glomerular capillary TN (GC-TN) and proteinuria, and between GC-DC and GC-TN, were studied in 27 biopsies showing chronic allograft nephropathy (CAN) lesions. In 14 patients (serum creatinine <2.0 mg/dl at biopsy), graft outcome was studied. Graft function 3 years after biopsy was classified as stable or deteriorated; the term ‘deteriorated’ was used if serum creatinine had increased 20% over baseline, or if the patient required dialysis. Results: In CAN, GC-TN correlated with GC-DC. Proteinuria in patients with intense GC-TN tended to increase during 1 year after biopsy. In graft outcome analysis, GC-TN was significantly lower in stable grafts than in deteriorated ones. Furthermore, all 3 patients demonstrating weak GC-TN without GC-DC returned to dialysis. Conclusion: TN immunostaining is a sensitive method to detect glomerular capillary injury with a predictive value for renal allograft dysfunction.

1.
Petersen VP, Olsen TS, Kissmeyer-Nielsen F, Bohman SO, Hansen HE, Hansen ES, Skov PE, Solling K: Late failure of human renal transplants. An analysis of transplant disease and graft failure among 125 recipients surviving for one to eight years. Medicine (Baltimore) 1975;54:45–71.
2.
Cheigh JS, Mouradian J, Susin M, Stubenbord WT, Tapia L, Riggio RR, Stenzel KH, Rubin AL: Kidney transplant nephrotic syndrome: Relationship between allograft histology and natural course. Kidney Int 1980;18:358–365.
3.
Bear RA, Aprile M, Sweet J, Cole EH: Proteinuria in renal transplant recipients: Incidence, cause, prognostic importance. Transplant Proc 1988;20:1235–1236.
4.
Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713–723.
5.
Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE: Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 1990;63:798–806.
6.
Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I: Tenascin in normal, reactive, hyperplastic and neoplastic tissue: Biologic and pathologic implications. Hum Pathol 1991;22:636–643.
7.
Truong LD, Pindur J, Barrios R, D’Agati V, Lechago J, Suki W, Majesky M: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994;45:201–210.
8.
Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, Hayry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozumi K, Myers BD, Nast CC, Olsen S, Racusen LC, Ramos EL, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, von Willebrand E, Yamaguchi Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411–422.
9.
Assad L, Schwartz MM, Virtanen I, Gould VE: Immunolocalization of tenascin and cellular fibronectins in diverse glomerulonephritis. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;63:307–316.
10.
Okada M, Takemura T, Murakami K, Hino S, Yoshioka K: Expression of tenascin in normal and diseased human kidneys. Jpn J Nephrol 1996;38:213–219.
11.
Gould VE, Martinez-Lacabe V, Virtanen I, Sahlin KM, Schwartz MM: Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 1992;67:71–79.
12.
Truong LD, Majesky M, Pindur J: Tenascin is synthesized and secreted by rat mesangial cells in culture and is present in extracellular matrix in human glomerular diseases. J Am Soc Nephrol 1994;4:1771–1777.
13.
Hedin U, Holm J, Hansson GK: Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype. Am J Pathol 1991;139:649–656.
14.
Mackie EJ, Scott-Burden T, Hahn AWA, Kern F, Bernhardt J, Regenass S, Weller A, Buhler FR: Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol 1992;141:377–388.
15.
Lenz O, Striker LJ, Jacot TA, Elliot SJ, Killen PD, Striker GE: Glomerular endothelial cells synthesize collagens but little gelatinase A and B. J Am Soc Nephrol 1998;9:2040–2047.
16.
Hohage H, Kleyer U, Brückner D, August C, Zidek W, Spieker C: Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron 1997;75:160–165.
17.
Nicholson ML, Bailey E, Williams S, Harris KPG, Furness PN: Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999;68:236–241.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.